14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 88 days ( 0 % )
Last Price $0.200 0 %
High/ Low $0.200 - $0.200 0%
Chg 7 Days N/A $0.200 $0.200
Chg 30 Days N/A $0.200 $0.200
Chg 12 mos -39.41 % $0.330 $0.200
Trend - 3 mos -7.23 % Width: 594.46 %
Trend - 12 mos -18.72 % Width: 1,139.16 %
Pred. range - 3 mos $0.121 - $0.84 -39.46 % - 320.45 %
Pred. range - 12 mos $0.0630 - $0.781 -68.50 % - 290.33 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell May 25, 2023 - 117 days
Long MA avg 12 mos Sell Aug 11, 2023 - 64 days
Short/Long MA avg 12 mos Sell Jun 22, 2023 - 99 days
Pivot Short Buy Aug 14, 2023 - 63 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinica... NYMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT